Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Autor: Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M.A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krüger, S., Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K -O, Thomas, R., Zander, T., Schultheis, A.M., Büttner, R., Wolf, J. ^*

Publikováno v: In Annals of Oncology October 2018 29(10):2068-2075

ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology

Autor: Heydt, C. ^*, Kostenko, A., Merkelbach-Bruse, S., Wolf, J., Büttner, R.

Publikováno v: In Annals of Oncology September 2016 27 Supplement 3:iii25-iii34

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.

Autor: Riedel R; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Fassunke J; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Scheel AH; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Scheffler M; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Heydt C; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Nogova L; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Michels S; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Fischer RN; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Eisert A; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Scharpenseel H; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., John F; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Ruge L; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Schaufler D; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany., Siemanowski J; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Ihle MA; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Wagener-Ryczek S; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Pappesch R; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Rehker J; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Bunck A; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department of Radiology, University of Cologne, Cologne, Germany., Kobe C; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department of Nuclear Medicine, University of Cologne, Cologne, Germany., Keil F; Institute of Pathology, University of Regensburg, Regensburg, Germany., Merkelbach-Bruse S; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Büttner R; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Institute of Pathology, University of Cologne, Cologne, Germany., Wolf J; Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Lung Cancer Group Cologne, Cologne, Germany. Electronic address: juergen.wolf@uk-koeln.de.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Jan; Vol. 19 (1), pp. 160-165. Date of Electronic Publication: 2023 Jul 08.

Incidental FOXL2 mutated adult granulosa cell tumour of the ovary with thecoma-like foci.

Autor: Fischer AK; Institute of Pathology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. Anne.Fischer1@uk-koeln.de., Schömig-Markiefka B; Institute of Pathology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany., Heydt C; Institute of Pathology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany., Ratiu D; Department Od Gynaecology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany., Mallmann P; Department Od Gynaecology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany., Meinel J; Institute of Pathology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany., Büttner R; Institute of Pathology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany., Schmidt D; Medical Care Center for Histology, Cytology and Molecular Diagnostics Trier, Max-Planck-Straße 5, 54296, Trier, Germany., Quaas A; Institute of Pathology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Publikováno v: Virchows Archiv : an international journal of pathology [Virchows Arch] 2023 Jul; Vol. 483 (1), pp. 117-124. Date of Electronic Publication: 2022 Nov 18.

[Biomarker MET in tumor pathology].

Autor: Ihle MA; Institut für Pathologie. Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, 50937, Köln, Deutschland. michaela.ihle@uk-koeln.de., Heydt C; Institut für Pathologie. Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, 50937, Köln, Deutschland.

Publikováno v: Pathologie (Heidelberg, Germany) [Pathologie (Heidelb)] 2023 May; Vol. 44 (3), pp. 193-196. Date of Electronic Publication: 2023 Mar 21.